Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Bacher

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Bone Marrow Transplantation|May 1, 2012
Evaluation of BM cytomorphology after allo-SCT in patients with AMLM Christopeit, K Miersch, E Klyuchnikov, et al.
Leukemia|August 12, 2014
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroupsM-T Krauth, T Alpermann, U Bacher, et al.
Bone Marrow Transplantation|June 3, 2008
EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCTS Ocheni, N Kroeger, T Zabelina, et al.
Leukemia|June 18, 2015
Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)A Pigneux, M Labopin, J Maertens, et al.
Bone Marrow Transplantation|May 12, 2009
Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donorsO W Neth, U Bacher, P Das, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Bone Marrow Transplantation|August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsN Kröger, T Zabelina, E Klyuchnikov, et al.
Hematological Oncology|August 31, 2025
CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of RadiotherapyJ T Jutzi, J Wampfler, C Ionescu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2012
Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experienceS Le Gouill, N Kröger, N Dhedin, et al.
Leukemia|November 14, 2013
Landscape of genetic lesions in 944 patients with myelodysplastic syndromesT Haferlach, Y Nagata, V Grossmann, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|May 1, 2012
Evaluation of BM cytomorphology after allo-SCT in patients with AMLM Christopeit, K Miersch, E Klyuchnikov, et al.
Leukemia|August 12, 2014
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroupsM-T Krauth, T Alpermann, U Bacher, et al.
Bone Marrow Transplantation|June 3, 2008
EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCTS Ocheni, N Kroeger, T Zabelina, et al.
Leukemia|June 18, 2015
Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)A Pigneux, M Labopin, J Maertens, et al.
Bone Marrow Transplantation|May 12, 2009
Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donorsO W Neth, U Bacher, P Das, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Bone Marrow Transplantation|August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsN Kröger, T Zabelina, E Klyuchnikov, et al.
Hematological Oncology|August 31, 2025
CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of RadiotherapyJ T Jutzi, J Wampfler, C Ionescu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2012
Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experienceS Le Gouill, N Kröger, N Dhedin, et al.
Leukemia|November 14, 2013
Landscape of genetic lesions in 944 patients with myelodysplastic syndromesT Haferlach, Y Nagata, V Grossmann, et al.
Pageof 4